Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AMRI

Albany Molecular Research (AMRI) Stock Price, News & Analysis

Albany Molecular Research logo

About Albany Molecular Research Stock (NASDAQ:AMRI)

Advanced Chart

Key Stats

Today's Range
$21.74
$21.74
50-Day Range
$21.74
$21.74
52-Week Range
$13.01
$22.17
Volume
N/A
Average Volume
872,120 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive AMRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albany Molecular Research and its competitors with MarketBeat's FREE daily newsletter.

AMRI Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Curia Unveils Brand Refresh at CPHI WW in Milan
See More Headlines

AMRI Stock Analysis - Frequently Asked Questions

Albany Molecular Research Inc (NASDAQ:AMRI) posted its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.21 by $0.14. The biotechnology company earned $102.80 million during the quarter, compared to analyst estimates of $107.20 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Albany Molecular Research investors own include Casella Waste Systems (CWST), Bristol Myers Squibb (BMY), Zevra Therapeutics (KMPH), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Alpha Lithium (APHLF) and Denison Mine (DNN).

Company Calendar

Last Earnings
5/10/2016
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:AMRI) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners